HEM Hemostemix Inc.

TSXV · CA · Healthcare · Biotechnology · hemostemix.com

0.0600CAD0.00%Mkt Cap: 9.24M $P/E: —4d ago

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which completed Phase II…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap9.24M USD

Enterprise Value11.69M USD

Revenue (TTM)—

Gross Profit—

Net Income (TTM)-3.43M USD

Revenue/Share—

Last Price0.0600 CAD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees—

CountryCA

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)-0.43

PEG—

EV/EBITDA-3.17

EV/Revenue—

P/S—

P/B-2.14

EPS (TTM)-0.03

EPS (Forward)-0.14

52W Range

0.040021% of range0.1350

52W High0.1350 CAD

52W Low0.0400 CAD

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE94.80%

ROA-556.61%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-3.30M USD

CapEx (TTM)—

FCF Margin—

FCF Yield-27.16%

Net Debt2.45M USD

Net Debt/EBITDA-0.67

Balance Sheet

Debt/Equity-0.72

Current Ratio0.13

Quick Ratio0.13

Book Value/Sh-0.03 CAD

Cash/Share0.0010 CAD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 CAD

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay DateDec 30, 2020

Splits

Last Split1:20

Split DateDec 30, 2020

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.211.44M

Float168.41M

Insiders16.63%

Institutions0.00%

Short Interest

Short Ratio0.9d

Short % Out.0.01%

Shares Short15.00K

Short (prev mo.)16.59K

Technical

SMA 500.0687 (-12.7%)

SMA 2000.0710 (-15.5%)

Beta0.67

S&P 52W Chg14.58%

Avg Vol (30d)30.38K

Avg Vol (10d)35.63K

Technical Indicators

RSI (14)38.8

MACD-0.0018

MACD Signal-0.0001

MACD Hist.-0.0018

BB Upper0.0811 CAD

BB Middle0.0693 CAD

BB Lower0.0574 CAD

BB Width34.14%

ATR (14)0.0031 CAD

Vol Ratio (20d)0.16x